Atorvastatin
- Generic Name
- Atorvastatin
- Brand Names
- Atorvaliq, Caduet, Lipitor, Lypqozet
- Drug Type
- Small Molecule
- Chemical Formula
- C33H35FN2O5
- CAS Number
- 134523-00-5
- Unique Ingredient Identifier
- A0JWA85V8F
- Background
Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively inhibit the enzyme hydroxymethylg...
- Indication
Atorvastatin is indicated for the treatment of several types of dyslipidemias, including primary hyperlipidemia and mixed dyslipidemia in adults, hypertriglyceridemia, primary dysbetalipoproteinemia, homozygous familial hypercholesterolemia, and heterozygous familial hypercholesterolemia in adolescent patients with failed dietary modifications.
...
- Associated Conditions
- Anginal Pain, Cardiovascular Complications, Cardiovascular Disease (CVD), Coronary Artery Disease (CAD), Coronary artery thrombosis, Dysbetalipoproteinemia, Fredrickson Type III lipidemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Hospitalizations, Hypertension, Essential Hypertension, Hypertriglyceridemias, Mixed Dyslipidemias, Mixed Hyperlipidemia, Myocardial Infarction, Non-familial hypercholesterolemia, Nonfatal Myocardial Infarction, Postoperative Thromboembolism, Primary Hypercholesterolemia, Stroke, Thrombosis, Transient Ischemic Attack, Elevation of serum triglyceride levels, Heterozygous familial hyperlipidemia, Non-familial hyperlipidemia, Primary Hyperlipidemia, Revascularization procedures
- Associated Therapies
- -
How Do Medicines Get Their Names?
Medication names are scientifically developed to ensure patient safety, with strict processes including chemical, generic, and brand names. The FDA and international bodies oversee these names to prevent errors and ensure global recognition.
Top 10 pharmaceutical companies in the world
Top pharmaceutical companies like Pfizer, Roche, Johnson & Johnson, Novartis, Merck, AstraZeneca, Sanofi, GSK, AbbVie, and Bayer lead in innovation, focusing on areas such as mRNA vaccines, cancer treatments, immunology, and gene therapy, shaping the future of healthcare through R&D investments and strategic pivots.
What to know about brand-name and generic drugs
The article explains the differences between brand-name and generic drugs, detailing the FDA approval process and how these medications impact patient treatment options. Brand-name drugs are original medications protected by patents, while generics, once the patent expires, must prove equivalency to the original. The main differences lie in cost, appearance, and sometimes formulation, with generics often preferred for cost-effectiveness.
Rapid Detection of SLCO1B1 Polymorphisms Using Duplex Fluorescence Mel
The study employs Duplex Fluorescence Melting Curve Analysis (DFMCA) to detect and genotype two significant SLCO1B1 polymorphisms (rs2306283 and rs4149056) in the Han Chinese population, demonstrating high sensitivity and specificity. The allele frequencies observed align with previous research, highlighting ethnic and geographical variations in SLCO1B1 polymorphisms, which influence drug metabolism and personalized medicine. DFMCA's advantages include simplicity, speed, and reduced risk of contamination, positioning it as a promising tool for clinical genetic testing and precision medicine.
Insilico Medicine appoints Carol Satler, MD.
Insilico Medicine appoints Carol Satler, M.D., PhD, as VP for Non-oncology Clinical Development, to lead validation of ISM001-055 for idiopathic pulmonary fibrosis and strategic planning for non-oncology assets. Satler, with 20+ years of experience at Pfizer, Sanofi, Bayer, Takeda/Millennium, Puretech Health, and Gilead, aims to accelerate clinical validation and bring transformative therapies to market using AI.
3 Magnificent S&P 500 Dividend Stocks Down 43%, 20%, and 53% to Buy and Hold Forever
Three S&P 500 dividend stocks—Pfizer, Realty Income, and Franklin Resources—are currently down 53%, 20%, and 43% respectively, offering potential 'forever' holdings with strong dividend yields of 5.8%, 4.9%, and 6%.
What Critics of Pfizer Are Getting Wrong
Starboard Value's proxy fight with Pfizer intensifies as critics target CEO Dr. Albert Bourla, alleging stock underperformance and overpaying in acquisitions. However, Pfizer's stock performance aligns with peers, and recent acquisitions show promising returns. The debate centers on Pfizer's strategic direction, with critics favoring short-term gains over long-term growth.
Keynoter Doug Long Sees Fragility, 'Pretty Anemic' Launches As He Looks Ahead to Retirement
Doug Long, IQVIA's VP of industry relations, warns of a fragile U.S. healthcare system in his PBMI keynote, citing issues like low cancer screening rates, poor returns for generic/biosimilar manufacturers, and pharmacy deserts. He criticizes the Inflation Reduction Act, noting only 26 new drugs launched in 2023, and 22 FDA approvals. Long, retiring next May, highlights challenges in retail pharmacy, opioid overdoses, prescription rejections, and declining oncology drug launches.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath